Cargando…

A case of high‐risk AML in a patient with advanced systemic mastocytosis

Aggressive SM + AML has limited therapeutic options. Even a strong combination of decitabine–venetoclax–midostaurin has a transient effect on AML and a mitigated effect on SM. Larger series are required to identify the best therapeutic strategy.

Detalles Bibliográficos
Autores principales:	Fazio, Manlio, Vetro, Calogero, Markovic, Uroš, Duminuco, Andrea, Parisi, Marina, Maugeri, Cinzia, Mauro, Elisa, Parrinello, Nunziatina Laura, Stagno, Fabio, Villari, Loredana, Triolo, Anna Maria, Stella, Stefania, Palumbo, Giuseppe A., Di Raimondo, Francesco, Romano, Alessandra, Zanotti, Roberta
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10352544/ https://www.ncbi.nlm.nih.gov/pubmed/37469366 http://dx.doi.org/10.1002/ccr3.7134

Ejemplares similares

Potential clinical impact of T-cell lymphocyte kinetics monitoring in patients with B cell precursors acute lymphoblastic leukemia treated with blinatumomab: a single-center experience
por: Duminuco, Andrea, et al.
Publicado: (2023)

Therapeutic innovation for multi-resistant candidemics: Synergy of isavuconazole and caspofungin association
por: Duminuco, Andrea, et al.
Publicado: (2021)

Saprochete capitata: Emerging Infections from Uncommon Microorganisms in Hematological Diseases
por: Duminuco, Andrea, et al.
Publicado: (2022)

PB1993: EXPRESSION OF NEO-201 MAY HELP IN THE DIFFERENTIAL DIAGNOSIS BETWEEN MYELODYSPLASTIC SYNDROMES AND ACUTE MYELOID LEUKEMIA
por: Duminuco, Andrea, et al.
Publicado: (2023)

Combined Inhibition of Bcl2 and Bcr-Abl1 Exercises Anti-Leukemia Activity but Does Not Eradicate the Primitive Leukemic Cells
por: Massimino, Michele, et al.
Publicado: (2021)

P1558: PROPHYLAXIS WITH TIXAGEVIMAB-CILGAVIMAB IN SINGLE-CENTER EXPERIENCE CAN REDUCE SEVERE COMPLICATIONS RELATED TO SARS-COV-2 INFECTION IN HEMATOLOGICAL PATIENTS
por: Duminuco, Andrea, et al.
Publicado: (2023)

Target Therapy for Extramedullary Relapse of FLT3-ITD Acute Myeloid Leukemia: Emerging Data from the Field
por: Duminuco, Andrea, et al.
Publicado: (2022)

PB2072: CIRCULATING CD71+ MYELOID PRECURSORS IN MGUS AND MULTIPLE MYELOMA: A PROSPECTIVE SURVEY
por: Parrinello, Nunziatina Laura, et al.
Publicado: (2023)

Immunological Deregulation in Classic Hodgkin Lymphoma
por: Romano, Alessandra, et al.
Publicado: (2014)

Immunological Dysregulation in Multiple Myeloma Microenvironment
por: Romano, Alessandra, et al.
Publicado: (2014)

Transient Leukemoid Reaction from T-Cell Large Granular Lymphocytes Post Autologous Stem Cell Transplant in a Patient Affected by Hodgkin Lymphoma
por: Duminuco, Andrea, et al.
Publicado: (2023)

Proteomic Analysis Reveals Autophagy as Pro-Survival Pathway Elicited by Long-Term Exposure with 5-Azacitidine in High-Risk Myelodysplasia
por: Romano, Alessandra, et al.
Publicado: (2017)

Off-Label Use of Venetoclax in Patients With Acute Myeloid Leukemia: Single Center Experience and Data From Pharmacovigilance Database
por: Gozzo, Lucia, et al.
Publicado: (2021)

Severe Gastrointestinal Toxicity Following the Use of Gilteritinib: A Case Series and Analysis of Postmarketing Surveillance Data
por: Gozzo, Lucia, et al.
Publicado: (2023)

Prediction of Survival and Prognosis Migration from Gold-Standard Scores in Myelofibrosis Patients Treated with Ruxolitinib Applying the RR6 Prognostic Model in a Monocentric Real-Life Setting
por: Duminuco, Andrea, et al.
Publicado: (2022)

Leishmania Infection during Ruxolitinib Treatment: The Cytokines-Based Immune Response in the Setting of Immunocompromised Patients
por: Duminuco, Andrea, et al.
Publicado: (2023)

Multiple Myeloma in 2023 Ways: From Trials to Real Life
por: Fazio, Manlio, et al.
Publicado: (2023)

The prognostic value of the myeloid-mediated immunosuppression marker Arginase-1 in classic Hodgkin lymphoma
por: Romano, Alessandra, et al.
Publicado: (2016)

Salvage Therapy of Multiple Myeloma: The New Generation Drugs
por: Romano, Alessandra, et al.
Publicado: (2014)

The first description of a singular case of synchronous chronic myelomonocytic leukemia and diffuse large b‐cell lymphoma
por: Romano, Alessandra, et al.
Publicado: (2021)

Bone turnover markers in patients with type 1 Gaucher disease
por: Giuffrida, Gaetano, et al.
Publicado: (2012)

Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia: Are Supporting Evidences Enough?
por: Brancati, Serena, et al.
Publicado: (2021)

Myeloid Derived Suppressor Cells (MDSCs) Are Increased and Exert Immunosuppressive Activity Together with Polymorphonuclear Leukocytes (PMNs) in Chronic Myeloid Leukemia Patients
por: Giallongo, Cesarina, et al.
Publicado: (2014)

Myelofibrosis and Survival Prognostic Models: A Journey between Past and Future
por: Duminuco, Andrea, et al.
Publicado: (2023)

Serum free light chains and multiple myeloma: Is it time to extend their application?
por: Markovic, Uros, et al.
Publicado: (2020)

Ruxolitinib treatment in myelofibrosis and polycythemia vera causes suboptimal humoral immune response following standard and booster vaccination with BNT162b2 mRNA COVID-19 vaccine
por: Palumbo, Giuseppe A., et al.
Publicado: (2023)

Chk1 Inhibition Restores Inotuzumab Ozogamicin Citotoxicity in CD22-Positive Cells Expressing Mutant p53
por: Tirrò, Elena, et al.
Publicado: (2019)

PB2093: OVERALL SURVIVAL IN RELAPSED-REFRACTORY MYELOMA PATIENTS DEPENDS ON CIRCULATING PLASMA CELLS QUANTITATION
por: Parrinello, Nunziatina Laura, et al.
Publicado: (2023)

High BCR::ABL1 Expression Defines CD34+ Cells with Significant Alterations in Signal Transduction, Short-Proliferative Potential and Self-Renewal Ability
por: Massimino, Michele, et al.
Publicado: (2023)

The NLR and LMR ratio in newly diagnosed MM patients treated upfront with novel agents
por: Romano, Alessandra, et al.
Publicado: (2017)

Mesenchymal Stem Cells (MSC) Regulate Activation of Granulocyte-Like Myeloid Derived Suppressor Cells (G-MDSC) in Chronic Myeloid Leukemia Patients
por: Giallongo, Cesarina, et al.
Publicado: (2016)

Monocytic myeloid‐derived suppressor cells as prognostic factor in chronic myeloid leukaemia patients treated with dasatinib
por: Giallongo, Cesarina, et al.
Publicado: (2017)

SPARC expression in CML is associated to imatinib treatment and to inhibition of leukemia cell proliferation
por: Giallongo, Cesarina, et al.
Publicado: (2013)

Reduced Absolute Count of Monocytes in Patients Carrying Hematological Neoplasms and SARS-CoV2 Infection
por: Romano, Alessandra, et al.
Publicado: (2022)

Lenalidomide and Pomalidomide Improve Function and Induce FcγRI/CD64 in Multiple Myeloma Neutrophils
por: Romano, Alessandra, et al.
Publicado: (2021)

Single segment of spleen autotransplantation, after splenectomy for trauma, can restore splenic functions
por: Toro, Adriana, et al.
Publicado: (2020)

Clinical Impact of the Immunome in Lymphoid Malignancies: The Role of Myeloid-Derived Suppressor Cells
por: Vetro, Calogero, et al.
Publicado: (2015)

Systemic Mastocytosis: Multidisciplinary Approach
por: Zanotti, Roberta, et al.
Publicado: (2021)

Role of Serum Free Light Chain Assay in Relapsed/Refractory Multiple Myeloma. A Real-Life Unicentric Retrospective Study
por: Markovic, Uros, et al.
Publicado: (2021)

Bone Marrow Mastocytosis: A Diagnostic Challenge
por: Zanotti, Roberta, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_3j1e9v747ep4f6jo3gomhoeus2